Form 4: Allogene Therapeutics Executive Sells Shares in Multiple Transactions

Deborah M. Messemer, an executive at Allogene Therapeutics, sold shares in multiple transactions at a weighted average price of $2.18.

Summary

• Deborah M. Messemer, an executive at Allogene Therapeutics, sold 9,136 shares of common stock on December 9, 2024.
• The shares were sold in multiple transactions at prices ranging from $2.16 to $2.21, with a weighted average price of $2.18.
• The total value of the shares sold was $15,762.29.
• A power of attorney document was also filed, authorizing Earl Douglas, Geoffrey Parker, Annie Yoshiyama, and Lillian Smith to act on behalf of Deborah Messemer for SEC filings related to her holdings.

Sentiment

Score: 5

Explanation: The document describes a routine stock sale by an executive, which is neither positive nor negative in itself. The sentiment is neutral.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often monitored by investors for insights into management's perspective on the company's future prospects. This sale by Deborah Messemer is a routine transaction and does not necessarily indicate a negative outlook for Allogene Therapeutics.

Comparison to Industry Standards

• Executive stock sales are a normal part of compensation and portfolio management in publicly traded companies.
• The sale by Deborah Messemer is similar to other executive stock sales in the biotechnology industry.
• The volume of shares sold is relatively small compared to the overall market capitalization of Allogene Therapeutics.

Stakeholder Impact

• The stock sale may have a minor impact on the stock price, but it is unlikely to have a significant effect on the company's overall performance or stakeholder value.

Key Dates

Keywords

Allogene Therapeutics, stock sale, insider trading, Deborah Messemer, common stock, SEC filing, power of attorney